PTC Therapeutics

E561093

PTC Therapeutics is a biopharmaceutical company focused on developing small-molecule and RNA-based therapies for rare genetic disorders and other serious diseases.

Try in SPARQL Jump to: Statements Referenced by

Statements (47)

Predicate Object
instanceOf biopharmaceutical company
public company
collaboratesWith Roche NERFINISHED
SMA Foundation NERFINISHED
conducts clinical trials
country United States of America
surface form: United States
develops RNA-based therapies
small-molecule therapies
engagesIn commercialization of medicines
drug discovery
preclinical development
focusesOn rare genetic disorders
serious diseases
foundedBy Stuart W. Peltz NERFINISHED
hasBusinessModel research and development of proprietary therapeutics
hasDrug Emflaza NERFINISHED
Evrysdi NERFINISHED
Translarna NERFINISHED
Upstaza NERFINISHED
hasDrugIndication Duchenne muscular dystrophy NERFINISHED
aromatic L-amino acid decarboxylase deficiency
spinal muscular atrophy
hasEmployeeType clinical development professionals
regulatory affairs professionals
research scientists
hasKeyPerson Matthew B. Klein NERFINISHED
Stuart W. Peltz NERFINISHED
hasMarket global rare disease market
hasTherapeuticArea central nervous system disorders
genetic diseases
metabolic disorders
neuromuscular disorders
oncology
headquartersLocation South Plainfield, New Jersey, United States NERFINISHED
industry biotechnology
pharmaceuticals
regulatoryRegion European Union NERFINISHED
Latin America NERFINISHED
United States NERFINISHED
researchFocus nonsense mutation readthrough
targetsPatientPopulation patients with rare diseases
pediatric patients
tradedAs NASDAQ:PTCT NERFINISHED
usesModality RNA splicing modulation
gene therapy
small molecules
website https://www.ptcbio.com

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

risdiplam developedBy PTC Therapeutics